Argenica Therapeutics Ltd
Save
99.80M
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. The company was incorporated in 2019 and is based in Nedlands, Australia.
Similar securities
Based on sector and market capitalization
Report issue